VYNE Therapeutics Inc. — Director's Dealing 2021

Jun 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: VYNE Therapeutics Inc. (VYNE)
CIK: 0001566044
Period of Report: 2021-06-18

Reporting Person: Zeronda Tyler (Interim CFO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	23395	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option	$5.92	2029-05-16	Common Stock (13504)		Direct
Stock Option	$10.68	2030-03-19	Common Stock (4375)		Direct
Stock Option	$7.80	2030-05-06	Common Stock (9375)		Direct
Stock Option	$6.68	2031-03-04	Common Stock (18834)		Direct

Footnotes

F1: This amount includes 18,853 shares underlying unvested restricted stock units that will vest over four years following the date of grant.

F2: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on June 30, 2020 and 6.25% of the shares vest on the last day of each quarter thereafter.

F3: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option vested on March 31, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.

F4: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on June 30, 2021 and 6.25% of the shares will vest on the last day of each quarter thereafter.

F5: The shares subject to the option vest over a period of 4 years. 25% of the shares subject to the option will vest on March 31, 2022 and 6.25% of the shares will vest on the last day of each quarter thereafter.